[The use of instenon in children with minimal brain dysfunction].
Minimal brain dysfunction (MBD) represents the most common type of neuropsychic disorders in childhood. Resulting in focal damages, underdevelopment and dysfunction of one or another cortical regions of brain hemispheres, MBD manifested in children as movement and speech disorders, dysgraphy, dyslexia, dyscalculia and attention deficit hyperactivity disorder. In the open controlled study, an efficacy of the complex nootropic medication "Instenon" was evaluated in the treatment of 59 MBD patients, aged 4-12 years. Control group included 27 children with MBD assigned to low polyvitamin (Sana Sol) doses. The treatment duration was 1 month. Before and after treatment, children with MBD underwent complex examination, which included parent's interviewing using structured questionnaire, general examination, with detailed analysis of complaints, neurological status investigation and psychological study. In the children taken instenon, distinct positive effect has been achieved in 71% of the cases, in control group--in 15%. Positive effect emerged in improvement of behavior characteristics, better school marks, movement, attention and memory indices, functions of psychic activity, organization, programming and control. When strictly keeping a scheme prescribed (gradual dose increase, drug taking in morning and day time), a risk for unfavorable side effects is minimal.
Zavadenko
N N
NN
Suvorinova
N Iu
NIu
Rumiantseva
M V
MV
Ovchinnikova
A A
AA
D000643:Ammonium Chloride / Q000627:therapeutic use; D001549:Benzamides / Q000008:administration & dosage / Q000627:therapeutic use*; D001927:Brain Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology*; D002125:Calcium Gluconate / Q000627:therapeutic use; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D007839:Functional Laterality / Q000502:physiology; D006592:Hexobendine / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011189:Potassium Chloride / Q000627:therapeutic use; D012720:Severity of Illness Index; D013806:Theophylline / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D001549:Benzamides; D004338:Drug Combinations; D000643:Ammonium Chloride; C094274:sanasol; D011189:Potassium Chloride; C001453:Instenon; D006592:Hexobendine; D013806:Theophylline; D002125:Calcium Gluconate